Clinical Trials

Date: 2017-12-19

Type of information: Presentation of results at a congress

phase: preclinical

Announcement: presentation of results at the 11th European Workshop on Immune Mediated Inflammatory Diseases

Company: OSE Immunotherapeutics (France)

Product: OSE-127 (Effi-7)

Action mechanism:

monoclonal antibody. Effi-7 is a monoclonal immunodulatory antibody targeting the CD127 receptor, the alpha chain of the interleukin-7 receptor (IL-7R) that blocks both the IL-7 and the internalization of the receptor. It therefore induces a powerful antagonist effect for better long-term control of the pathogenic T lymphocytes. The strategy of blocking the IL-7 is different from conventional methods, as well as the latest anti-inflammatory drugs used in clinic, and has demonstrated efficacy in restoring the impaired immune balance in autoimmune diseases of the bowel in several clinical models.
Effi-7 is being developed as part of the consortium EFFIMab, led by OSE Immunotherapeutics. The Effi-7 project is co-financed by Bpifrance in the amount of € 9.1 million (for a total amount of €20 million).
OSE Immunotherapeutics has signed a license option agreement with Servier in December 2016 for the development and commercialization of OSE-127.

Disease: inflammatory bowel diseases including Crohn's disease and ulcerative colitis

Therapeutic area: Autoimmune diseases - Gastrointestinal diseases - Inflammatory diseases

Country:

Trial details:

Latest news:

• On December 19, 2017, OSE Immunotherapeutics announced that the company has presented new data on OSE-127 (Effi-7) at the 11th European Workshop on Immune Mediated Inflammatory Diseases. The oral presentation, entitled "Interleukin-7 receptor pathway controls human T cell homing to the gut and predicts response to anti-TNF? in patients with inflammatory bowel disease" further supports the potential of OSE-127 (Effi-7) for the treatment of inflammatory bowel diseases, including Crohn's disease and ulcerative colitis. The presentation reported results from a transcriptomic analysis of colon biopsies in more than 500 patients and 100 controls in a large database available for specialized bioinformaticians. This analysis showed that both interleukin-7 receptor (IL-7R, target of OSE-127) and IL-7R signaling signature transcripts are strongly overexpressed in colon biopsies from patients with inflammatory bowel diseases, including Crohn's disease and ulcerative colitis, in therapeutic failure following treatment with corticosteroids, immunosuppressors or anti-TNF? treatment. Moreover, the level of IL-7R overexpression in colon biopsies from these patients was significantly correlated and predictive of non-response to anti-TNF? treatment.
OSE Immunotherapeutics is now looking forward to initiating clinical phase for OSE-127 in 2018.